Vertex PharmaceuticalsVRTX
Recorded

Vertex Pharmaceuticals Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration29 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Akash TewariAnalyst

That is my cue. I really do appreciate it. I think this is the last fireside chat for today, but by no means am I not excited to host the Vertex management team. I am serious here. Susie, Manisha, I really do appreciate both of you making the trip over to London. I know that Reshma might come in next year. We are going to try to convince her. We will see. Either way, very, very appreciative of your time. I can tell you from a research perspective, Vertex is one of the names we are most excited about in large-cap biotech. We do think 2027 is setting up to be probably the most impactful year in terms of diversification away from cystic fibrosis, but then also a lot of strength in that franchise as well. Looking forward to the discussion.

Akash TewariAnalyst

I will hand it off to you for some intro remarks, and we will get started.

Susie LisaSVP of Investor Relations

Yeah. Thanks very much, Akash and the Jefferies team, for having us. Thanks everyone in the room for sticking through to the bitter end here on Tuesday. I think it is shaping up to be a really exciting year, but we have got a lot of exciting stuff still to do in 2026. Most notably, we are eagerly awaiting our November 30 PDUFA date for povetacicept in immunoglobulin A nephropathy. I am excited for that, and I am sure we will go into more detail there. Also, by the end of the year, you will have phase II proof-of-concept data for our DM1, our myotonic dystrophy type 1 compound. As you shift into 2027, early in the year in the first quarter, you will have interim analysis phase III data from our AMPLITUDE study. This looks at inaxaplin in APOL1-mediated kidney disease patients. Really excited to see that.

Susie LisaSVP of Investor Relations

We had essentially a patient population expansion study read out earlier this year in AMPLIFIED. We are excited to see the full phase III interim analysis. If that is positive, then you could see us file for accelerated approval based upon that endpoint. Also, in the first half of 2027, you will see the first results from a proof-of-concept study in povetacicept looking at myasthenia gravis. We fully enrolled that study. By the middle of the year, we would expect to see data from two phase III studies looking at suzetrigine, which is our NaV1.8 inhibitor, in diabetic peripheral neuropathy. These are the first phase IIIs for us in peripheral neuropathic pain or in chronic pain. Those are both set to complete enrollment, both of those trials, by the end of this year. They are 12-week studies, so that puts us about mid-year for data there.

Susie LisaSVP of Investor Relations

There is more throughout the course of the year, but maybe I will stop there and then talk about whatever you would like. I think as we continue to pursue additional launches this year in 2026, we have talked about $500 million plus in revenue from non-CF products. You add to that with the recent acquisition of Crinetics, and PALSONIFY will get us north of that because that is just JOURNAVX and CASGEVY. We look for even more growth from non-CF products in 2027 while continuing to see a solid outlook for CF.

Akash TewariAnalyst

Understood. I was at ESMO, but my team was at ASN. Otherwise, I would have been there. I do think your team made an interesting argument on efficacy for povetacicept, and I think one that maybe will age well, right? Because I think a lot of people say, "Okay, we have eGFR stabilization. They all look the same." But your team has been insistent when it comes to the consistency around geographies, hematuria, proteinuria getting under certain levels. I think you are really alluding that the puck may move. What doctors care about now versus what they may care about two, three years down the line might actually end up being different.

Akash TewariAnalyst

Talk to me about your confidence that povetacicept is differentiated from an efficacy perspective beyond just proteinuria, and what are you hearing on the ground in terms of the evolving landscape and endpoints that doctors are going to increasingly focus on?

Susie LisaSVP of Investor Relations

Sure. Yeah. Thanks for the very good question. We do think that we have potential best-in-class efficacy with povetacicept. I will go into detail. We know we believe we have best-in-class patient administration or convenience factors, and hopefully we can talk about that too. But with respect to efficacy, recall that at our interim analysis, we had a 52% reduction in proteinuria, and that was just at 36 weeks. Competitors who saw a similar rate of reduction was actually out to 40 weeks. We know proteinuria continues to decline, so that was an earlier snap of it. We had greater than 80% reduction in resolution of hematuria, and we also had 42% of patients getting to KDIGO guidelines. I think how physicians are thinking about this, first off, povetacicept patients are otherwise healthy, typically younger. Average age of diagnosis is in their mid-40s.

Susie LisaSVP of Investor Relations

No patient, no physician wants blood or protein in their urine. I think even small differences in proteinuria reduction compounded over time for a lifelong therapy could result in differences that are meaningful in terms of kidney function. Not necessarily do we think that stable is stable, but acting sooner, faster, having faster rates of decline could result in overall better clinical outcomes in terms of potentially staving off progression to dialysis, transplant, or even death. That will be a long time to prove, but we are excited with the profile of povetacicept being able to take that forward. As I mentioned, on the patient administration aspect, we think a clear advantage there given that we are once every four weeks dosing with an auto-injector with very low dose, 0.46 mL. We also have lower viscosity than peers, so it is less painful.

Susie LisaSVP of Investor Relations

As I mentioned, at home with an auto-injector versus peers who are every four weeks are today with a prefilled syringe at much higher dosages, or other peers are at weekly dosing.

Akash TewariAnalyst

Mm. Now, one of the things I have noticed, every other company I really talk to, when it comes to IgAN and eGFR, one-year interim, one-year interim, you actually, you really do stand out. There is not a single other company I talk to who actually talks about the importance of two-year data, A, for global regulators, but B, as you think about building a dataset where maybe it takes a little more time for the hematuria or the proteinuria, for povetacicept to differentiate on efficacy, right? Talk to me about data that you are going to generate long-term that would maybe support your view that any levels of proteinuria may actually lead to a worse outcome for patients, and how can you maybe generate that data internally at Vertex?

Akash TewariAnalyst

Talk to us about why you are such an outlier about looking for that two-year interim, I mean, that two-year endpoint, and what do you think that gives you from an advantage perspective about the global market opportunity for these drugs?

Susie LisaSVP of Investor Relations

Yeah, that's really a key part of it, there's only a pathway today currently for accelerated approval in the U.S. I should also mention we have filed for accelerated approval in Kingdom of Saudi Arabia, where there's a pathway there. Otherwise, in Europe and in the Asian markets, it is a firm two-year eGFR endpoint. While it's a significantly large rare market opportunity in the U.S., we estimate 160,000 patients are today biopsy-confirmed, diagnosed with IgAN, and we'd estimate a similar size population in Europe, that 330 sort of type of number pales in comparison to what we'd estimate as 1.5 million or 1.6 million globally. We view Asia as the much larger patient opportunity. Just today, we saw the Chinese government approve two B-cell inhibitor agents for reimbursement in China, and I think that speaks to the need there.

Susie LisaSVP of Investor Relations

We have partnered commercially with Ono Pharma in Japan and surrounding countries and with Zai Lab in China and surrounding countries, excuse me. I do think that that longer endpoint will begin to, we believe, bear out some of our thesis about less proteinuria sooner is always a better thing. Less hematuria, better hematuria resolution sooner is a better thing, because it shouldn't be there in your urine, and let's try and preserve as much nephron function as we can.

Akash TewariAnalyst

I just thought of this question now because you mentioned Zai and Ono you're partnered with, and there is this dynamic of the MFN of it all, right? I hosted Pfizer earlier today. There was a panel, I think, yesterday which really said, "This is not a red wave, blue wave dynamic. This kind of a more equitable share of healthcare expenditure is a growing issue, and it's not going to go away regardless of whether there's a Democrat or Republican in office in the United States." You have very uniquely partnered. You're working with external partners when you're thinking about the ex-U.S. opportunity.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day